The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
How Ligands Illuminate GPCR Molecular Pharmacology
Open accessAbstract
G protein-coupled receptors (GPCRs), which are modulated by a variety of endogenous and synthetic ligands, represent the largest family of druggable targets in the human genome. Recent structural and molecular studies have both transformed and expanded classical concepts of receptor pharmacology and have begun to illuminate the distinct mechanisms by which structurally, chemically, and functionally diverse ligands modulate GPCR function. These molecular insights into ligand engagement and action have enabled new computational methods and accelerated the discovery of novel ligands and tool compounds, especially for understudied and orphan GPCRs. These advances promise to streamline the development of GPCR-targeted medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Slightly more than half of the non-olfactory GPCRs have annotated drugs and small molecules targeting them53,54,61; see also TABLE 1.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A recent analysis indicates, however, that a handful of GPCRs — mainly biogenic amine, muscarinic and opioid receptors — represent the most abundantly targeted receptors for FDA-approved medications53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“Alterations in GPCR signalling are implicated in the pathogenesis and treatment of neuropsychiatric55, immunological56, gastrointestinal57,58, cardiac59, renal, hormonal, infectious60 and many other disorders53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“GPCRs represent the largest family of druggable targets in the human genome9, with between 20% and 30% of approved drugs acting on them53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“GPCRs are membrane-bound, cell-surface receptors that transduce signals via interactions with heterotrimeric G proteins, arrestins and other cellular transducers53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [53]
In the citing paper
“For covalent inhibitors, one of their chief advantages is potentially more durable inhibition at the PPI site leading to improved pharmacology in vivo [117, 118].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Orphan receptor ligand discovery by pickpocketing pharmacological neighbors
Ngo, T., Ilatovskiy, A. V., Stewart, A. G., Coleman, J. L. J., McRobb, F. M., Riek, R., Graham, R. M., Abagyan, R. A., Kufareva, I., & Smith, N. J. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2266 · Cited by 48
RetractedCrystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
ZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009
Fredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Thrombin signalling and protease-activated receptors
Coughlin, S. R. (2000) · Nature · doi:10.1038/35025229 · Cited by 2,495
Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409
Diversity of G Proteins in Signal Transduction
Simon, M. I., Strathmann, M., & Gautam, N. (1991) · Science · doi:10.1126/science.1902986 · Cited by 2,016
Roth, B. L. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.040 · Cited by 1,742
Self-citationTransduction of Receptor Signals by ß-Arrestins
Lefkowitz, R. J., & Shenoy, S. K. (2005) · Science · doi:10.1126/science.1109237 · Cited by 1,729
Structure of a nanobody-stabilized active state of the β2 adrenoceptor
Rasmussen, S. G. F., Choi, H., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., DeVree, B. T., Rosenbaum, D. M., Thian, F. S., Kobilka, T. S., et al. (2011) · Nature · doi:10.1038/nature09648 · Cited by 1,709
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Self-citationLéan, A. D., Stadel, J. M., & Lefkowitz, R. J. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)79672-9 · Cited by 1,606
Molecular signatures of G-protein-coupled receptors
Venkatakrishnan, A., Deupí, X., Lebon, G., Tate, C. G., Schertler, G. F. X., & Babu, M. M. (2013) · Nature · doi:10.1038/nature11896 · Cited by 1,534
β-Arrestin-Dependent Formation of β 2 Adrenergic Receptor-Src Protein Kinase Complexes
Luttrell, L. M., Ferguson, S. S. G., Daaka, Y., Miller, W. E., Maudsley, S. R., Rocca, G. J. D., Lin, F., Kawakatsu, H., Owada, K. M., Luttrell, D. K., et al. (1999) · Science · doi:10.1126/science.283.5402.655 · Cited by 1,473
β-Arrestin acts as a clathrin adaptor in endocytosis of the β2-adrenergic receptor
Goodman, O. B., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., Keen, J. H., & Benovic, J. (1996) · Nature · doi:10.1038/383447a0 · Cited by 1,383
Samama, P., Cotecchia, S., Costa, T., & Lefkowitz, R. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53442-6 · Cited by 1,256
Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor
KUNISHIMA, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., Nakanishi, S., Jingami, H., & Morikawa, K. (2000) · Nature · doi:10.1038/35039564 · Cited by 1,249
β-Arrestin: a Protein that Regulates β-adrenergic Receptor Function
Lohse, M. J., Benovic, J., Codina, J., Caron, M. G., & Lefkowitz, R. J. (1990) · Science · doi:10.1126/science.2163110 · Cited by 1,222
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,216
Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin
Farrens, D., Altenbach, C., Yang, K., Hubbell, W. L., & Khorana, H. G. (1996) · Science · doi:10.1126/science.274.5288.768 · Cited by 1,179
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Self-citationStructure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist
Chien, E. Y. T., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A., Shi, L., Newman, A. H., Javitch, J. A., Cherezov, V., et al. (2010) · Science · doi:10.1126/science.1197410 · Cited by 1,134
Self-citationFunctional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B. K., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,131
Self-citationOperational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 1,106
Structure-Function of the G Protein–Coupled Receptor Superfamily
Katritch, V., Cherezov, V., & Stevens, R. C. (2012) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032112-135923 · Cited by 1,096
Self-citationTreatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902903 · Cited by 1,017
Regulation of serotonin-2C receptor G-protein coupling by RNA editing
Burns, C. M., Chu, H., Rueter, S. M., Hutchinson, L. K., Canton, H., Sanders-Bush, E., & Emeson, R. B. (1997) · Nature · doi:10.1038/387303a0 · Cited by 1,010 · cited 1×
“Indeed, this constitutive activity has been amply documented in both recombinant (Burns et al., 1997) and endogenous (Arvanitakis et al., 1997) expression systems.”
BackgroundStructure-based discovery of opioid analgesics with reduced side effects
Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D. G., Corder, G. F., Levit, A., Kling, R. C., Bernat, V., Hübner, H., et al. (2016) · Nature · doi:10.1038/nature19112 · Cited by 978
Self-citationStructural Basis for Allosteric Regulation of GPCRs by Sodium Ions
Liu, W., Chun, E., Thompson, A. A., Chubukov, P., Xu, F., Katritch, V., Han, G. W., Roth, C., Heitman, L. H., IJzerman, A. P., et al. (2012) · Science · doi:10.1126/science.1219218 · Cited by 952
Self-citationStructural insights into µ-opioid receptor activation
Huang, W., Manglik, A., Venkatakrishnan, A., Laeremans, T., Feinberg, E. N., Sanborn, A. L., KATO, H. E., Livingston, K. E., Thorsen, T. S., Kling, R. C., et al. (2015) · Nature · doi:10.1038/nature14886 · Cited by 920
Activation and allosteric modulation of a muscarinic acetylcholine receptor
Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. M., et al. (2013) · Nature · doi:10.1038/nature12735 · Cited by 902
Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation
Lebon, G., Warne, T., Edwards, P. C., Bennett, K. A., Langmead, C. J., Leslie, A. G. W., & Tate, C. G. (2011) · Nature · doi:10.1038/nature10136 · Cited by 892
Trends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853
The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors
Alexander, S. P. H., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Southan, C., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13348 · Cited by 851
Teratogen-Mediated Inhibition of Target Tissue Response to Shh Signaling
Cooper, M. K., Porter, J. A., Young, K. E., & Beachy, P. A. (1998) · Science · doi:10.1126/science.280.5369.1603 · Cited by 848
Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser
Kang, Y., Zhou, X. E., Gao, X., He, Y., Liu, W., Ishchenko, A., Barty, A., White, T. A., Yefanov, O. M., Han, G. W., et al. (2015) · Nature · doi:10.1038/nature14656 · Cited by 818
Self-citationSalvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist
Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., & Rothman, R. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182234399 · Cited by 784
Self-citationPathway and mechanism of drug binding to G-protein-coupled receptors
Dror, R. O., Pan, A. C., Arlow, D. H., Borhani, D. W., Maragakis, P., Shan, Y., Xu, H., & Shaw, D. E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104614108 · Cited by 737
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Self-citationTemporally precise in vivo control of intracellular signalling
Airan, R. D., Thompson, K. R., Fenno, L. E., Bernstein, H. L., & Deisseroth, K. A. (2009) · Nature · doi:10.1038/nature07926 · Cited by 715
Biased Signaling Pathways in β 2 -Adrenergic Receptor Characterized by 19 F-NMR
Liu, J. J., Horst, R., Katritch, V., Stevens, R. C., & Wüthrich, K. (2012) · Science · doi:10.1126/science.1215802 · Cited by 706
Self-citationStructural Features for Functional Selectivity at Serotonin Receptors
Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F., et al. (2013) · Science · doi:10.1126/science.1232808 · Cited by 706
Self-citationCrystal Structure of the Human Cannabinoid Receptor CB1
Hua, T., Vemuri, K. V., Pu, M., Qu, L., Han, G. W., Wu, Y., Zhao, S., Shui, W., Li, S., Korde, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.10.004 · Cited by 702
Self-citationStructural Insights into the Dynamic Process of β2-Adrenergic Receptor Signaling
Manglik, A., Kim, T. H., Masureel, M., Altenbach, C., Yang, Z., Hilger, D., Lerch, M. T., Kobilka, T. S., Thian, F. S., Hubbell, W. L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.043 · Cited by 671
Arvanitakis, L., Geras‐Raaka, E., Varma, A., Gershengorn, M. C., & Cesarman, E. (1997) · Nature · doi:10.1038/385347a0 · Cited by 670
Bunzow, J. R., Sonders, M. S., Arttamangkul, S., Harrison, L. M., Zhang, G., Quigley, D. I., Darland, T., Suchland, K. L., Pasumamula, S., Kennedy, J. L., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1181 · Cited by 651
DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647
β-Arrestin-biased ligands at seven-transmembrane receptors
Violin, J. D., & Lefkowitz, R. J. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.006 · Cited by 606
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M. L.-H., Qu, Q., Tarrasch, J. T., Li, S., Kobilka, T. S., Kobilka, B. K., et al. (2017) · Nature · doi:10.1038/nature22394 · Cited by 594
GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling
Thomsen, A. R. B., Plouffe, B., Cahill, T. J., Shukla, A. K., Tarrasch, J. T., Dosey, A. M., Kahsai, A. W., Strachan, R. T., Pani, B., Mahoney, J. P., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.004 · Cited by 587
Morello, J.-P., Salahpour, A., Laperrière, A., Bernier, V., Arthus, M., Lonergan, M., Petäjä‐Repo, U. E., Angers, S., Morin, D., Bichet, D. G., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8688 · Cited by 558
Opiate Agonists and Antagonists Discriminated by Receptor Binding in Brain
Pert, C. B., Pasternak, G. W., & Snyder, S. H. (1973) · Science · doi:10.1126/science.182.4119.1359 · Cited by 545
Structural Basis for Molecular Recognition at Serotonin Receptors
Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G. W., Liu, W., Huang, X., Vardy, E., et al. (2013) · Science · doi:10.1126/science.1232807 · Cited by 531
Self-citationStructure of the agonist-bound neurotensin receptor
White, J. F., Noinaj, N., Shibata, Y., Love, J. D., Kloss, B., Xu, F., Gvozdenovic‐Jeremic, J., Shah, P., Shiloach, J., Tate, C. G., et al. (2012) · Nature · doi:10.1038/nature11558 · Cited by 527
Allosteric sodium in class A GPCR signaling
Katritch, V., Fenalti, G., Abola, E. E., Roth, B. L., Cherezov, V., & Stevens, R. C. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.03.002 · Cited by 525
Self-citationMolecular control of δ-opioid receptor signalling
Fenalti, G., Giguère, P. M., Katritch, V., Huang, X., Thompson, A. A., Cherezov, V., Roth, B. L., & Stevens, R. C. (2014) · Nature · doi:10.1038/nature12944 · Cited by 508
Self-citationAdrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody
Ring, A. M., Manglik, A., Kruse, A. C., Enos, M. D., Weis, W. I., García, K. C., & Kobilka, B. K. (2013) · Nature · doi:10.1038/nature12572 · Cited by 500
International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G Protein–Coupled Receptors
Hamann, J., Aust, G., Araç, D., Engel, F. B., Formstone, C. J., Fredriksson, R., Hall, R. A., Harty, B. L., Kirchhoff, C., Knapp, B., et al. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009647 · Cited by 489
A Simple Method for Quantifying Functional Selectivity and Agonist Bias
Kenakin, T., Watson, C., Muniz-Medina, V. M., Christopoulos, A., & Novick, S. J. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200111m · Cited by 488
Phase-plate cryo-EM structure of a class B GPCR–G-protein complex
Liang, Y.-L., Khoshouei, M., Radjainia, M., Zhang, Y., Glukhova, A., Tarrasch, J. T., Thal, D. M., Furness, S. G. B., Christopoulos, G., Coudrat, T., et al. (2017) · Nature · doi:10.1038/nature22327 · Cited by 481
Drugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479 · cited 3×
“The most infamous example is likely the anti-obesity drug fenfluramine, which was withdrawn because of association with valvular heart disease in many individuals (Allen and Roth, 2011; Roth, 2007).”
BackgroundSelf-citationCrystal Structure of an LSD-Bound Human Serotonin Receptor
Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A., Levit, A., Lansu, K., Schools, Z. L., Che, T., Nichols, D. E., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.033 · Cited by 474
Self-citationβ-Adrenergic Receptor Kinase: Primary Structure Delineates a Multigene Family
Benovic, J., DeBlasi, A., Stone, W. C., Caron, M. G., & Lefkowitz, R. J. (1989) · Science · doi:10.1126/science.2552582 · Cited by 444
3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone
Scanlan, T. S., Suchland, K. L., Hart, M. E., Chiellini, G., Huang, Y., Kruzich, P. J., Frascarelli, S., Crossley, D. A., Bunzow, J. R., Ronca-Testoni, S., et al. (2004) · Nature Medicine · doi:10.1038/nm1051 · Cited by 439
Structure of class B GPCR corticotropin-releasing factor receptor 1
Hollenstein, K., Kean, J., Bortolato, A., Cheng, R. K. Y., Dore, A. S., Jazayeri, A., Cooke, R. M., Weir, M., & Marshall, F. H. (2013) · Nature · doi:10.1038/nature12357 · Cited by 423
Inverse agonist activity of beta-adrenergic antagonists.
Chidiac, P., Hébert, T. E., Valiquette, M., Dennis, M., & Bouvier, M. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10022-9 · Cited by 372
Two disparate ligand-binding sites in the human P2Y1 receptor
Zhang, D., Gao, Z., Zhang, K., Kiselev, E., Crane, S., Wang, J., Paoletta, S., Yi, C., Ma, L., Zhang, W., et al. (2015) · Nature · doi:10.1038/nature14287 · Cited by 369
Self-citationAllen, J., Yost, J. M., Setola, V., Chen, X., Sassano, M. F., Chen, M., Peterson, S. M., Yadav, P. N., Huang, X., Feng, B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104807108 · Cited by 364
Self-citationWacker, D., Fenalti, G., Brown, M. A., Katritch, V., Abagyan, R. A., Cherezov, V., & Stevens, R. C. (2010) · Journal of the American Chemical Society · doi:10.1021/ja105108q · Cited by 358
Self-citationAllosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation
Changeux, J., & Christopoulos, A. (2016) · Cell · doi:10.1016/j.cell.2016.08.015 · Cited by 353
The role of kinetic context in apparent biased agonism at GPCRs
Herenbrink, C. K., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P. J., Capuano, B., Sexton, P. M., Charlton, S. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10842 · Cited by 348
Staus, D. P., Strachan, R. T., Manglik, A., Pani, B., Kahsai, A. W., Kim, T. H., Wingler, L. M., Ahn, S., Chatterjee, A., Masoudi, A., et al. (2016) · Nature · doi:10.1038/nature18636 · Cited by 330
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
Moore, A. R., Ceraudo, E., Sher, J. J., Guan, Y., Shoushtari, A. N., Chang, M. T., Zhang, J. Q., Walczak, E. G., Kazmi, M. A., Taylor, B. S., et al. (2016) · Nature Genetics · doi:10.1038/ng.3549 · Cited by 325
Comprehensive characterization of the Published Kinase Inhibitor Set
Elkins, J. M., Fedele, V., Szklarz, M., Abdul Azeez, K. R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., Huang, X.-P., Roth, B. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3374 · Cited by 323
Self-citationLigand discovery from a dopamine D3 receptor homology model and crystal structure
Carlsson, J., Coleman, R. G., Setola, V., Irwin, J. J., Fan, H., Schlessinger, A., Šali, A., Roth, B. L., & Shoichet, B. K. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.662 · Cited by 309
Self-citationCongreve, M., Andrews, S. P., Dore, A. S., Hollenstein, K., Hurrell, E., Langmead, C. J., Mason, J. S., Ng, I. W., Tehan, B. G., Zhukov, A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201376w · Cited by 305
In silico design of novel probes for the atypical opioid receptor MRGPRX2
Lansu, K., Karpiak, J., Liu, J., Huang, X.-P., McCorvy, J. D., Kroeze, W. K., Che, T., Nagase, H., Carroll, F. I., Jin, J., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2334 · Cited by 293
Self-citationStructure-based discovery of β 2 -adrenergic receptor ligands
Kolb, P., Rosenbaum, D. M., Irwin, J. J., Fung, J. J., Kobilka, B. K., & Shoichet, B. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812657106 · Cited by 291
Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65
Huang, X.-P., Karpiak, J., Kroeze, W. K., Zhu, H., Chen, X., Moy, S. S., Saddoris, K. A., Nikolova, V. D., Farrell, M. S., Wang, S., et al. (2015) · Nature · doi:10.1038/nature15699 · Cited by 284
Self-citationMultidimensional Tracking of GPCR Signaling via Peroxidase-Catalyzed Proximity Labeling
Paek, J., Kalocsay, M., Staus, D. P., Wingler, L. M., Pascolutti, R., Paulo, J. A., Gygi, S. P., & Kruse, A. C. (2017) · Cell · doi:10.1016/j.cell.2017.03.028 · Cited by 272
Intracellular allosteric antagonism of the CCR9 receptor
Oswald, C., Rappas, M., Kean, J., Dore, A. S., Errey, J. C., Bennett, K. A., Deflorian, F., Christopher, J. A., Jazayeri, A., Mason, J. S., et al. (2016) · Nature · doi:10.1038/nature20606 · Cited by 267
Cerione, R. A., Codina, J., Benovic, J., Lefkowitz, R. J., Birnbaumer, L., & Caron, M. G. (1984) · Biochemistry · doi:10.1021/bi00315a003 · Cited by 249
Christopoulos, A., Changeux, J., Catterall, W. A., Fabbro, D., Burris, T. P., Cidlowski, J. A., Olsen, R. W., Peters, J. A., Neubig, R. R., Pin, J., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.008862 · Cited by 246
Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells
Nobles, M., Benians, A., & Tinker, A. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504778102 · Cited by 223
Extra-helical binding site of a glucagon receptor antagonist
Jazayeri, A., Dore, A. S., Lamb, D., Krishnamurthy, H., Southall, S. M., Baig, A. H., Bortolato, A., Koglin, M., Robertson, N. J., Errey, J. C., et al. (2016) · Nature · doi:10.1038/nature17414 · Cited by 217
Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors
Allen, J. A., & Roth, B. L. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100553 · Cited by 216
Self-citationWhite, K. L., Robinson, J. E., Zhu, H., DiBerto, J. F., Polepally, P. R., Zjawiony, J. K., Nichols, D. E., Malanga, C. J., & Roth, B. L. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216820 · Cited by 212
Self-citationRahmeh, R., Damian, M., Cottet, M., Orcel, H., Mendre, C., Durroux, T., Sharma, K. S., Durand, G., Pucci, B., Trinquet, E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201093109 · Cited by 203
Interaction of G protein coupled receptors and cholesterol
Gimpl, G. (2016) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2016.04.006 · Cited by 202
Pharmacogenomic and Structural Analysis of Constitutive G Protein–Coupled Receptor Activity
Smit, M. J., Vischer, H. F., Bakker, R. A., Jongejan, A., Timmerman, H., Pardo, L., & Leurs, R. (2006) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105126 · Cited by 194
Pan, Y., Metzenberg, A. B., Das, S., Jing, B., & Gitschier, J. M. (1992) · Nature Genetics · doi:10.1038/ng1092-103 · Cited by 181
New insights from structural biology into the druggability of G protein-coupled receptors
Mason, J. S., Bortolato, A., Congreve, M., & Marshall, F. H. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.02.005 · Cited by 173
Activation mechanism of endothelin ETB receptor by endothelin-1
Shihoya, W., Nishizawa, T., Okuta, A., Tani, K., Dohmae, N., Fujiyoshi, Y., Nureki, O., & Doi, T. (2016) · Nature · doi:10.1038/nature19319 · Cited by 168
Christopher, J. A., Aves, S. J., Bennett, K. A., Dore, A. S., Errey, J. C., Jazayeri, A., Marshall, F. H., Okrasa, K., Serrano‐Vega, M. J., Tehan, B. G., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00892 · Cited by 166
Asano, T., Katada, T., Gilman, A. G., & Ross, E. M. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42705-0 · Cited by 160
Pathway and Mechanism of Drug Binding to G-Protein-Coupled Receptors
Dror, R. O., Pan, A. C., Arlow, D. H., Borhani, D. W., Maragakis, P., Shan, Y., Xu, H., & Shaw, D. E. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2011.11.2241 · Cited by 155
Endogenous Allosteric Modulators of G Protein–Coupled Receptors
van der Westhuizen, E. T., Valant, C., Sexton, P. M., & Christopoulos, A. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221606 · Cited by 145
Biased Ligands for Better Cardiovascular Drugs
DeWire, S. M., & Violin, J. D. (2011) · Circulation Research · doi:10.1161/circresaha.110.231308 · Cited by 145
The antagonism of acetyl choline by atropine
Clark, A. J. (1926) · The Journal of Physiology · doi:10.1113/jphysiol.1926.sp002315 · Cited by 143
Urs, N. M., Gee, S. M., Pack, T. F., McCorvy, J. D., Evron, T., Snyder, J. C., Yang, X., Rodriguiz, R. M., Borrelli, E., Wetsel, W. C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614347113 · Cited by 143
Self-citationPrescription Drug Spending Trends In The United States: Looking Beyond The Turning Point
Aitken, M. L., Berndt, E. R., & Cutler, D. (2008) · Health Affairs · doi:10.1377/hlthaff.28.1.w151 · Cited by 141
Fluorescent Pirenzepine Derivatives as Potential Bitopic Ligands of the Human M1 Muscarinic Receptor
Tahtaoui, C., Parrot, I., Klotz, P., Guillier, F., Galzi, J., Hibert, M., & Ilien, B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040800a · Cited by 104
Gloriam, D. E. I., Foord, S. M., Blaney, F. E., & Garland, S. L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900319e · Cited by 101
NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor
O’Connor, C., White, K. L., Doncescu, N., Didenko, T., Roth, B. L., Czaplicki, G., Stevens, R. C., Kurt Wüthrich, A., & Milon, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510117112 · Cited by 96
Self-citationRoth, B. L., & Kroeze, W. K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.654764 · Cited by 88
Self-citationMolecular interaction fingerprint approaches for GPCR drug discovery
Vass, M., Kooistra, A. J., Ritschel, T., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.007 · Cited by 67
From Heptahelical Bundle to Hits from the Haystack
Kooistra, A. J., Roumen, L., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2013) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-407865-9.00015-7 · Cited by 51
Kenakin, T., & Boselli, C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22846-4 · Cited by 42
Hitchhiking on the heptahelical highway: structure and function of 7TM receptor complexes
Tesmer, J. J. G. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.36 · Cited by 34
Wardman, J. H., Gomes, I., Bobeck, E. N., Stockert, J. A., Kapoor, A., Bisignano, P., Gupta, A., Mezei, M., Kumar, S., Filizola, M., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aac8035 · Cited by 34
Lanzafame, A., Christopoulos, A., & Mitchelson, F. J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36766-7 · Cited by 32
1 Rhodopsin Mutations in Congenital Night Blindness
McAlear, S. D., Kraft, T. W., & Gross, A. K. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1399-9_30 · Cited by 21
Dillon, G. M., Lubbers, L. S., Ferguson, M. T., Lao, J. Z., Huang, R. R., Xiao, J. C., Fong, T. M., Hale, J. J., Rupprecht, K. M., Miao, S., et al. (2011) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283423d7e · Cited by 12
Opportunities and challenges of the 2016 target landscape
Lafferty‐Whyte, K., Mormeneo, D., & Marimon, M. D. F. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.263 · Cited by 11
Flagged first, then by citations
Cited by
Sorted by citations
Molecular Dynamics Simulation for All
Hollingsworth, S. A., & Dror, R. O. (2018) · Neuron · doi:10.1016/j.neuron.2018.08.011 · Cited by 3,522
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask‐Andersen, M., Schiöth, H. B., & Gloriam, D. E. I. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,714
G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
Sriram, K., & Insel, P. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111062 · Cited by 1,258
“Data such as those presented here may allow for more accurate evaluation of interactions and off-target effects of approved drugs with GPCRs (Allen and Roth, 2011; Wacker et al., 2017), as well as providing opportunities for novel repurposing of approved drugs.”
BackgroundFree Fatty Acid Receptors in Health and Disease
Kimura, I., Ichimura, A., Ohue‐Kitano, R., & Igarashi, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00041.2018 · Cited by 1,063
La Merrill, M. A., Vandenberg, L. N., Smith, M. T., Goodson, W., Browne, P., Patisaul, H. B., Guyton, K. Z., Kortenkamp, A., Cogliano, V. J., Woodruff, T. J., et al. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0273-8 · Cited by 1,005
Metadata
- Authors
- Wacker, D., Stevens, R. C., & Roth, B. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Southern California (US)
- Corresponding author
- Roth, Bryan L.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 170
- Issue
- 3
- Pages
- 414-427
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5560499
- OpenAlex
- W2741191097
- Cited by
- 560
- References
- 115
- Citations by year
- 2026: 33 · 2025: 46 · 2024: 56 · 2023: 51 · 2022: 68 · 2021: 75 · 2020: 73 · 2019: 75 · 2018: 70 · 2017: 12
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institute of Health (RO1MH112205, UO1MH104974, U19MH82441, PO1DA035764)
- Michael Hooker Distinguished Professorship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- G protein-coupled receptors, GPCR pharmacology, ligand binding, ligand-receptor interactions, orphan G protein-coupled receptor, tool compounds, computational drug discovery, GPCR structure
- MeSH terms
- Animals, Humans, Ligands, Models, Molecular, Signal Transduction, Receptors, G-Protein-Coupled, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
